Dogwood Therapeutics (DWTX) M&A Announcement summary

Deal rationale and strategic fit

• Virios Therapeutics and Wex Pharmaceuticals merged to form Dogwood Therapeutics, creating a diversified pipeline focused on non-opioid pain and antiviral therapies, including Halneuron (a NaV1.7 inhibitor) and IMC-1/IMC-2 antiviral programs for fibromyalgia and long COVID.

• The merger leverages both companies' expertise and track records in developing and commercializing blockbuster pain medications, aiming to address large unmet needs in pain management and post-viral syndromes.

• The combined entity benefits from FDA Fast Track designations for Halneuron and IMC-1, enhancing regulatory momentum.

Financial terms and conditions

• Strategic financing from CK Life Sciences and existing cash provides approximately $23 million in working capital, funding operations through Q4 2025 and supporting Halneuron Phase 2b development.

• The transaction is an all-stock deal, with Sealbond (Wex's parent) receiving 211,383 common shares and 2,108.3854 non-voting convertible preferred shares, representing about 94% of the combined company on a fully diluted basis.

• A 25-for-1 reverse stock split is implemented to facilitate the business combination and restore Nasdaq compliance, effective October 9, 2024.

• Virios shareholders as of October 17th receive a contingent value right (CVR) tied to future milestone payments from IMC-1 or IMC-2 partnering.

Synergies and expected cost savings

• The merger creates a diversified pipeline with late-stage assets in pain and antiviral therapeutics, leveraging combined R&D and commercialization expertise.

• Combining teams with extensive experience in pain drug development is expected to accelerate R&D and commercialization.